← Back to Patent Explorer
US5474935A Expired / Lapsed US ⏱️ 0.0 years remaining

Adeno-associated virus (AAV)-based eucaryotic vectors

Assignee: United States Department of Health and Human Services
•
Filing: 1993-11-03
•
Granted: 1995-12-12
•
Expires: 2013-11-03
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The present invention relates to adeno-associated virus (AAV)-based eucaryotic vectors and uses thereof. Such vectors may, for example, be used to down regulate any targeted viral or cellular gene whose sequence is known. Furthermore, the vectors may also be used to cause the expression of proteins.

Inventors

  • 👤 Saswati Chatterjee
  • 👤 K. K. Wong, Jr.

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-03 23:35
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; C12N15/1131; C12N15/1132; C07; C07K; C07K14/00; C07K14/005; C12N15/63; C12N15/79; C12N15/85; C12N15/86; A; A61; A61K; A61K38/00; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/16011; C12N2740/16311; C12N2740/16322; C12N2750/00; C12N2750/00011; C12N2750/14011; C12N2750/14111; C12N2750/14141; C12N2750/14143

Claims Analysis

Total Claims: 14
Claim 1
Independent Claim 59 words
An AAV-based vector that is suitable for transferring a heterologous DNA fragment into cells in vitro, comprising: (a) vector pWC3, (b) a heterologous promoter oriented so as to promote transcription towards the AAV polyadenylation signal of said pWC3 vector, and (c) a heterologous DNA fragment, wherein said heterologous DNA fragment is under the regulatory control of said heterologous promoter.
Claim 2
Dependent Claim 59 words
An AAV-based vector that is suitable for transferring a heterologous DNA fragment into cells in vitro, comprising: (a) vector pWC3, (b) a heterologous promoter oriented so as to promote transcription towards the AAV polyadenylation signal of said pWC3 vector, and (c) a heterologous DNA fragment, wherein said heterologous DNA fragment is under the regulatory control of said heterologous promoter.
Claim 3
Dependent Claim 25 words
An AAV-based vector according to claim 1, wherein said heterologous DNA fragment encodes an antisense polynucleotide sequence that is complementary to a targeted RNA sequence.
Claim 4
Dependent Claim 21 words
An AAV-based vector according to claim 1, wherein said heterologous DNA fragment is a gene that encodes a protein of interest.
Claim 5
Dependent Claim 80 words
An AAV-based vector according to claim 2, further comprising: (d) a second heterologous promoter oriented so as to promote transcription in a direction opposite to said heterologous promoter of (b), and (e) a second heterologous DNA fragment, wherein said second heterologous DNA fragment is either a gene that encodes a selectable marker or is a gene that encodes an enzymatically measurable marker protein, and wherein said second heterologous DNA fragment is under the regulatory control of said second heterologous promoter.
Claim 6
Dependent Claim 18 words
An AAV-based vector according to claim 4, wherein said targeted RNA sequence is ICP4 of herpes simplex virus.
Claim 7
Dependent Claim 16 words
An AAV-based vector according to claim 4, wherein said targeted RNA sequence is E1a of adenovirus.
Claim 8
Dependent Claim 15 words
An AAV-based vector according to claim 4, wherein said targeted RNA sequence is HIV-1 TAR.
Claim 9
Dependent Claim 12 words
An AAV-based vector according to claim 7, wherein said vector is pCWRSV-HIVAlpha-Neo.
Claim 10
Dependent Claim 17 words
An AAV-based vector according to claim 1, wherein said heterologous promoter is the Rous sarcoma virus promoter.
Claim 11
Dependent Claim 6 words
An AAV-based vector which is pWC3.
Claim 12
Dependent Claim 6 words
An AAV-based vector which is pWC3.
Claim 13
Dependent Claim 6 words
An AAV-based vector which is pCWRSV.
Claim 14
Dependent Claim 6 words
An AAV-based vector which is pCWRSV.

References Cited (Backward Citations)

US4689320A Cited
US4797368A Cited
US4751180A Cited
US4889802A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1998-12-11 1999-06-12 1999-12-12 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2002-12-11 2003-06-12 2003-12-12 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2006-12-11 2007-06-12 2007-12-12 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag